Second Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

作者
Maite Hartwig,Sunday Ocheni,Nicolaus Martin Kröger,Tatjana Zabelina,Evgeny Klyuchnikov,Svetlana Asenova,H. Kabisch,R. Erttmann,Axel Rolf Zander,Ulrike Bacher
出处
期刊:Blood [Elsevier BV]
卷期号:112 (11): 4308-4308
标识
DOI:10.1182/blood.v112.11.4308.4308
摘要

Abstract Introduction: In acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), relapse after allogeneic stem cell transplantation (SCT) occurs with frequencies of 30–80% in dependence on risk profiles. Selected patients are offered a 2. allo-SCT. As the number of studies is limited, we here performed retrospective analysis of 20 consecutive MDS and AML pts who received at least 2 allografts from related/unrelated donors from 2000–2007. Patients: There were 4 children and 16 adults who received ≥2 allo-SCTs (10 males, 10 females; 2–63 years, median 38 yy). 14 pts had de novo AML, 3 pts s-AML, 2 MDS RAEB-1; one child had juvenile myelomonocytic leukemia (JMML). 19 pts received two allo-SCTs-18 due to another relapse after the 1. allo-SCT, one due to secondary graft failure after 1. SCT. One pt with MDS had 3 allo-SCTs due to relapses. 13/20 pts received treatment before the 2. allo-SCT, but only 6/20 achieved complete remission (CR). 10/20 pts had unfavorable cytogenetics. The median interval between the 1. and 2. allo-SCTs was 20 months (range 2–47 mo). Median disease free survival (DFS) after the 1. SCT was 16 months (range 3–45 mo). Characterization of 2. allo-SCTs: 4/20 second allo-SCTs were performed from related donors (3 HLA-identical, one haploidentical). 16 SCTs were performed from unrelated donors (HLA matched: n= 8, -mismatched: n=8). In 10 cases, the 2. allo-SCTs was performed from different, in 10 cases from the same donor. Reduced intensity conditioning was applied to 16 pts, myeloablative to 4 pts. Antithymocyte globuline was administered to 12/20 pts. One pt received bone marrow, 19 pts peripheral blood stem cells. Immunosuppression was performed in most pts by cyclosporine A plus short-course MTX or mycophenolate mofetil. Outcomes: Leukocyte engraftment was achieved in 16/20 cases with a median interval of 13 days (r. 10–24 d). 3 pts died prior to engraftment. One pt had secondary graft failure being followed by a 2. allo-SCT. CR was achieved by 16/20 pts. At the time of this report, 5/20 pts are still alive after a median follow-up of 15 months (r. 2–36 mo), three of those in CR with follow-ups of 7, 22, and 36 months. 9/20 pts developed relapse (45%), of whom 2 received donor lymphocytes. Median DFS after the 2. SCT was 7 months (range <1–38 mo). One patient received a 3. allo-SCT after another relapse of AML, but died 8 months after 3rd SCT due to treatment related mortality (TRM). The TRM rate was 7/20 pts (35%) either due to sepsis and multiorgan failure, fungal pneumonia, or acute GvHD. AGvHD (II–IV) was described in 11/20 pts (55%). Chronic GvHD developed in 5/20 pts. Two of those 3 pts, who remained in stable CR, had unfavorable karyotypes. They had developed relapse after 3, 28, and 45 months following the 1. SCT. Two achieved CR before the 2. allo-SCT. In two cases, HLA-mismatched SCTs were performed being followed by extensive cGVHD. All had reduced conditioning before SCT. One of those, a male pt aged 16 years, primarily received no immunosuppression. Following severe intestinal aGvHD after 3 weeks tacrolimus and steroids were started. Discussion: Despite a high rate of reduced intensity conditioning, TRM (35%) and relapse rate were high (45%). However, single pts seemed to benefit from a 2. SCT, even in case of unfavourable karyotypes or when no complete remission was achieved before the 2. SCT, and here also in one case with an early relapse after the 1. SCT. Thus, it seems difficult to predict which patients might have a benefit from this approach. Research should focus on the optimization of conditioning regimens especially for recipients of a 2. SCT and try to provide concepts for immunosuppression in this specific situation due to the high relapse risk.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
iitj发布了新的文献求助10
1秒前
余香的应助被yy采纳,获得10
1秒前
yuchuncheng完成签到,获得积分0
2秒前
gycao2025发布了新的文献求助10
2秒前
lzl007完成签到 ,获得积分0
4秒前
4秒前
Yolo完成签到 ,获得积分20
6秒前
特特特特特完成签到,获得积分10
6秒前
哈基米这一块完成签到,获得积分10
6秒前
Fly完成签到,获得积分10
6秒前
6秒前
胡杨树2006完成签到,获得积分10
7秒前
Fan完成签到 ,获得积分0
7秒前
椰子云的应助被邢一采纳,获得10
7秒前
冷cool完成签到,获得积分10
8秒前
Lucas完成签到,获得积分10
8秒前
8秒前
8秒前
dd完成签到,获得积分10
8秒前
毛啊毛完成签到,获得积分10
10秒前
10秒前
森林木发布了新的文献求助10
10秒前
qhebdb完成签到 ,获得积分10
11秒前
米豆完成签到 ,获得积分10
12秒前
123456qqqq发布了新的文献求助50
12秒前
dd发布了新的文献求助10
12秒前
12秒前
锦诗完成签到,获得积分10
13秒前
贪玩的水壶完成签到 ,获得积分10
13秒前
762323661完成签到,获得积分10
13秒前
wtian1221完成签到,获得积分10
14秒前
Nidhogg完成签到,获得积分10
14秒前
deer完成签到,获得积分10
14秒前
leave完成签到,获得积分10
15秒前
CarryLJR发布了新的文献求助10
15秒前
会盟发布了新的文献求助10
15秒前
15秒前
zs关闭了zs的文献求助
16秒前
DavidSun完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159151
求助须知:如何正确求助?哪些是违规求助? 9554617
关于积分的说明 21719982
捐赠科研通 7748814
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552091
邀请新用户注册赠送积分活动 2471436